PHARMACOLOGICAL AND TOXICOLOGICAL PROPERTIES OF ANTICOAGULANTOINTMENT

Golib Nazarov; Maruf Khudaiberdiev; Shavkat Salikhov; Nazarova Sarvinoz; Nurmuhammedova Vazira

doi:10.17605/OSF.IO/4Q2DM

Authors

Golib Nazarov PhD Student Institute of Bioorganic Chemistry Acad. A.S. Sadykov Academy of Sciences of the Republic of Uzbekistan
Maruf Khudaiberdiev Professor, Institute of Bioorganic Chemistry named after Academician A.S. Sadykov of the Academy of Sciences of the Republic of Uzbekistan
Shavkat Salikhov Academician, Director of the Institute of Bioorganic Chemistry named after Academician A.S. Sadykov of the Academy of Sciences of the Republic of Uzbekistan Institute of Bioorganic Chemistry named after Academician A.S. Sadykov of the Academy of Sciences of the Republic of Uzbekistan
Nazarova Sarvinoz Assistant, Tashkent Institute of Chemical Technology, Uzbekistan, Tashkent
Nurmuhammedova Vazira Associate Professor,Tashkent Institute of Chemical Technology, Uzbekistan, Tashkent

DOI:

https://doi.org/10.17605/OSF.IO/4Q2DM

Keywords:

Safinol, salicylic acid, ε -amino-enanthic acid, ointment.

Abstract

Treatment of thrombosis and embolism is currently one of the urgent problems of medicine. It is known that the body has universal resistance to a sudden increase in blood clotting, and only a sharp violation of the neuro-humoral regulation of hemostasis leads to vascular wall damage and the formation of blood clots.This paper presents the results of research on the development of its dosage form - safinol ointment and also pharmacological and toxicological properties

Downloads

Download data is not yet available.

References

Hirsh J., Anand S.S., Halperin J.L., Fuster V. // Mechanism of Action and Pharmacology of Unfractionated Heparin // Arteriosclerosis, Thrombosis, and Vascular Biology. — 2001. — V. 21. — P. 1094-1096.

Hirsh J., O’Donnell M., Eikelboom J.W. Beyond Unfractionated Heparin and Warfarin: Current and Future Advances // Circulation. — 2007. — V. 216. — P. 552-560.

Reich L.M., Folsom A.R., Key N.S. et al. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism // Journal of Thrombosis and Haemostasis. — 2006. — V. 4, № 9. — P. 1909-1913.

Wille-Jorgensen P., Jorgensen L.N., Crawford M. Asymptomatic postoperative deep vein thrombosis and the development of postthrombotic syndrome. A systematic review and meta-analysis // Thrombosis &Haemostasis. — 2005. — V. 93. — P. 236.

Eriksson B.I., Borris L.C., Dahl O.E. et al. A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement // Circulation. — 2006. — V. 114. — P. 2374-2381.

Eriksson B.I., Borris L.C., Friedman R.J. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty // New England Journal of Medicine. — 2008. — V. 358. — P. 2765-2775.

Escher R. Extensive venous thrombosis following administration of high-dose glucocorticosteroids and tranexamic acid in relapsed Evans syndrome // Blood Coagulation & Fibrinolysis. — 2008. — Vol. 19. — Issue 7. — Р. 741-742.